Trial Profile

SJiMB21: Phase 2 Study of Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Cyclophosphamide (Primary) ; Filgrastim (Primary) ; Filgrastim (Primary) ; Methotrexate (Primary) ; Methotrexate (Primary) ; Pegfilgrastim (Primary) ; Topotecan (Primary) ; Vincristine (Primary)
Indications Medulloblastoma
Focus Therapeutic Use
Acronyms SJiMB21

Most Recent Events

19 Dec 2022 Planned initiation date changed from 1 Dec 2022 to 1 Jan 2023.
30 Nov 2022 Planned initiation date changed from 1 Nov 2022 to 1 Dec 2022.
24 Sep 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com